History of acute pancreatitis Baseline characteristics Age - 55.85 yr Female sex - 57.1% Average body weight - 210 lbs (96 kg) Average BMI - 34.65 Type 2 diabetes - 55.9% Average ALT - 67.85 U/liter Average AST - 53.0 U/liter Fibrosis stage 2 - 31.3% Fibrosis stage 3 - 68.8% Randomized treatment groups Group 1 (534 patients): Semaglutide with a target dose of 2.4 mg once weekly Group 2 (266 patients): Placebo The starting dose of semaglutide was 0.25 mg once weekly, which was increased every 4 weeks to once-weekly doses of 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg until the target dose of 2.4 mg was reached after the 16-week dose-escalation period
BPC-157 (Body Protection Compound-157) is a synthetic peptide made of 15 amino acids (a pentadecapeptide) derived from a protective protein naturally found in gastric juice and the stomach lining
A 2022 cohort of 31 genetically confirmed patients demonstrated 2-grade improvement in muscle power within 3 months of 2060 mg kg 1 day 1 oral riboflavin, with sustained biochemical normalization at two-year follow-up (23)
This is higher than the 4% discontinuation rate in the placebo group
GPs are bound by patient confidentiality and are there to support, not judge
I just want you to know we're still waiting on big definitive results here, especially when we talk about Alzheimer's